Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 37  

 
   Table of Contents      
ORIGINAL ARTICLE
Year : 2012  |  Volume : 11  |  Issue : 2  |  Page : 65-69

18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors


1 Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
2 Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
3 Astra Zeneca, Alderley Park, Macclesfield, USA

Date of Web Publication10-Nov-2012

Correspondence Address:
Ingrid M. E. Desar
Department of Medical Oncology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500HB Nijmegen
Netherlands
Login to access the Email id


DOI: 10.4103/1450-1147.103413

PMID: 23372439

Rights and Permissions
   Abstract 

Selumetinib (AZD6244, ARRY-142886) is a potent, selective, uncompetitive inhibitor of MEK 1 / 2, part of the RAF/MEK/ERK protein kinase signal cascade, which is responsible for tumor. This pilot study was used to explore if 18  F-fluoro-l-thymidine (FLT), a thymidine analogue positron emission tomography (PET) tracer and a surrogate marker for proliferation, can be used as an early predictor of response for patients with solid cancers treated with Selumetinib. FLT-PET scans were performed in four patients at baseline and after 2 weeks of treatment with Selumetinib. FLT uptake in tumors was analyzed qualitatively and quantitatively by measuring standard uptake value (SUV) max in regions of interest (ROI). Results were compared to computed tomography (CT) scans (baseline and after 8 weeks), which were evaluated using the response evaluation criteria in solid tumors (RECIST) 1.0 criteria. One patient with melanoma showed both a qualitative and quantitative decrease in FLT uptake associated with a decrease in sum of longest diameter of 12% RECIST on CT evaluation. Another patient who had colorectal carcinoma (CRC) showed a significant increase in FLT uptake with initially stable, but eventually progressive disease on CT. The other two patients (one with melanoma and one with CRC) showed no significant changes in FLT uptake, whereas CT evaluation showed progressive disease. This is the first report describing changes in FLT-PET in patients receiving Selumetinib. In two patients, changes in FLT uptake as early as after 2 weeks of treatment were consistent with CT results after 8 weeks. Biomarkers to predict and evaluate treatment the outcome of targeted therapies are highly warranted. These initial results need further investigation.

Keywords: F-18 FLT, PET-CT, Selumetinib, treatment response


How to cite this article:
Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AN, Cantarini MV, van der Graaf WT, Oyen WJ. 18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors. World J Nucl Med 2012;11:65-9

How to cite this URL:
Desar IM, Gilles R, van Herpen CM, Timmer-Bonte AN, Cantarini MV, van der Graaf WT, Oyen WJ. 18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors. World J Nucl Med [serial online] 2012 [cited 2020 Jul 8];11:65-9. Available from: http://www.wjnm.org/text.asp?2012/11/2/65/103413


   Introduction Top


The intracellular Ras-regulated Raf/MEK/ERK protein kinase signal cascade is a key pathway involved in cellular proliferation and survival. A strong correlation between deregulation of this pathway and uncontrolled cell proliferation has been demonstrated. [1] Selumetinib (AZD6244, ARRY-142886) is a potent, selective, uncompetitive inhibitor of MEK ½, developed as targeted therapy to treat solid cancers. A favorable toxicity, pharmacokinetic, and pharmacodynamic profile has been observed in phase I studies and phase II studies focusing on melanoma and colorectal cancer (CRC). [2],[3],[4] The development of targeted agents requires identification and better understanding of positive predictive biomarkers of clinical response to these agents. Currently, the CT Response Evaluation Criteria in Solid Tumors (RECIST) are mostly used to evaluate response. [5] These RECIST guidelines are based on the sum of one-dimensional measurements of the greatest diameter of the tumor and/or metastases. [5],[6] However, treatment with targeted therapies is cytostatic rather than cytotoxic, and can result in necrosis and cavitation without a change in lesion (or tumor) size, leading to an underestimation of therapeutic efficacy. Imaging techniques able to predict treatment outcome in an early phase of treatment are warranted. Molecular imaging may enable alternative evaluation procedures for these new drugs and enable the early change to an alternative therapy if no functional response is indicated. Recently the functional imaging technique of positron emission tomography (PET) using the radiopharmaceutical tracer 18 F-fluorodeoxyglucose (FDG) has been found to be a useful method for response monitoring in various malignancies. [7],[8],[9],[10],[11] However, FDG is a tracer for glucose metabolism, which does not always reflect proliferation activity. The PET agent 18 F-fluoro-l-thymidine (FLT) has been introduced for imaging of cell proliferation. FLT is a thymidine analogue, which is retained in proliferating cells through the activity of the enzyme thymidine kinase-1, which is expressed during the DNA synthesis phase of the cell cycle. [12] FLT-PET has been applied for the assessment of proliferation rate in different tumors. [13],[14],[15],[16],[17],[18] In this pilot study, we assessed the effect of Selumetinib on tumor cell proliferation in patients with a variety of solid tumors by FLT-PET-CT and determined whether changes in FLT uptake can potentially be used as an early predictive biomarker for treatment response.


   Materials and Methods Top


Patients

This single-institution study was conducted in conjunction with Phase I clinical trial of the capsule formulation of Selumetinib (NCT00463814) in patients with solid tumors. [2] In this study, patients with advanced solid cancer refractory to standard therapies or for whom no conventional therapies exists were treated with oral Selumetinib twice daily in a dose escalation schedule. As part of this study protocol, an evaluation CT scan was performed after every two cycles (i.e. at 8 weekly intervals of treatment with Selumetinib).

Patients participating in the FLT-PET side study had to have at least one tumor deposit of at least 2 cm outside the liver and axial skeleton. All patients gave written informed consent and both studies were approved by the local ethical committee.

FLT-PET

FLT-PET scans were performed at baseline and after 2 weeks of treatment. The scans were performed on an integrated PET-CT scanner (Siemens/Biograph) using a static whole body protocol (hips to base of skull) 1 h after administration of 250 MBq FLT.

The FLT-PET images were analyzed both visually for any tumor targeting and quantitatively for changes in FLT uptake. Quantitative assessment was realized by drawing CT-derived 3D regions of interest (ROI) over the tumors, with both a threshold of 50% and 70% of the maximum FLT-activity via an automatic algorithm. Standardized uptake values (SUVs) were calculated using the concentration of FLT in the volume of interest (VOI) as measured by PET, divided by the injected dose per kg body weight as a normalization factor.

Evaluation

FLT-PET scans were analyzed by two nuclear medicine physicians. Only lesions outside of the liver and axial skeleton, with a diameter of 2 cm or more, which were also measured on CT, were evaluated. Based on two recent studies by de Langen et al. and Wahl et al., any changes in SUVmax greater than 30% were considered as significant and medically relevant, independent of day-to-day variability. [19],[20] CT scans were analyzed using the RECIST 1.0 guidelines. [6] Quantitative (mean SUVmax of measured lesions) FLT-PET results were compared with the results of the radiological evaluation with CT-scan based on RECIST 1.0 criteria.


   Results Top


In four patients, both baseline and follow-up FLT-PET-CTs were performed. Two patients had metastasized melanoma and two patients had advanced/metastatic CRC. One patient with melanoma showed both a qualitative and quantitative decrease in FLT uptake, correlating with a decrease in sum of diameters of 12% applying RECIST to CT evaluation [Figure 1] and [Figure 2]. Another patient who had CRC showed a significant increase in FLT uptake with initially (at 8 weeks) stable disease, but eventually progressive disease on CT. The other two patients (one with melanoma and one with CRC) showed no significant changes in FLT uptake, whereas CT evaluation showed progressive disease [Table 1].
Figure 1: F-18 FLT PET/CT scan. Coronal images: (a) Before treatment and (b) after treatment. A female patient with pleural metastases of a melanoma, showing decreased FLT uptake in the pleural metastases after treatment with Selumetinib for 2 weeks (Patient No. 1) [Table 1]

Click here to view
Figure 2: F-18 FLT PET/CT scan. Transaxial images: (a) Before treatment and (b) after treatment. A female patient with pleural metastases of a melanoma, showing decreased FLT uptake in the pleural metastases after treatment with Selumetinib for 2 weeks (Patient No. 1) [Table 1]

Click here to view
Table 1: Changes in mean SUVmax compared to CT changes according to RECIST after Selumetinib therapy in four patients with metastatic melanoma or metastatic colorectal carcinoma

Click here to view



   Discussion Top


In the new era of targeted therapies, there is a need for early identification of therapy responding and non-responding patients, in order to be able to change therapy, thereby working toward personalized medicine. Response monitoring for targeted therapies demands more specific diagnostic modalities than conventional imaging alone. Differentiation between vital tumor and fibrosis or necrosis is not possible by using morphological features as in RECIST. Furthermore, with functional and molecular imaging techniques, one could prevent a patient from unnecessarily suffering from drug side effects by differentiating responders from non-responders in an early stage of treatment.

As mentioned before, PET with FDG already has an established role in monitoring various anti-cancer therapies such as targeted therapies in malignant gastrointestinal stromal tumors. [10] This has led to the creation of the recently developed PET Response Criteria in Solid Tumors (PERCIST). [20]

Beyond FDG, more specific imaging biomarkers for PET have been developed of which a reasonable amount is already in clinical stage like 18 F-16α-17-fluoroestradiol ( 18 F-FES), 18 F-galacto-RGD, and 18 F-FLT, which was used in this study. [21]

However, PET is not the only imaging modality with potential in early response monitoring in clinical oncology. Different magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) techniques for functional and molecular imaging have been developed.

One of them is dynamic contrast-enhanced MRI (DCE-MRI) in which the kinetics of contrast agent inflow into the tumor after intravenous injection of the agent is followed. [22] Since tumor angiogenesis is associated with an increase in vessel permeability, this can be measured using DCE-MRI techniques. [23] Morgan et al. found that in patients treated with an anti-angiogenic vascular endothelial growth factor receptor tyrosine kinase inhibitor, there were significantly greater reductions in a pharmacokinetic parameter that was related to vessel permeability in patients who showed a positive response to treatment than in those who had progressive disease. [24]

Furthermore, multimodality imaging has potential role in clinical response monitoring, whereas PET/CT and single-photon emission computed tomography (SPECT) CT are already widely used for the evaluation of cancer. [25] However, the major drawback of these techniques is that they are combined by software and not acquired simultaneously. Recently, Judenhover et al. have performed simultaneously FLT-PET and MRI in a mouse model for colon carcinoma. This system was able to image three functional imaging techniques, PET, functional MRI, and MRS with morphological MRI. [26]

No fully statistically powered human studies on FLT-PET for cancer therapy response monitoring have been performed. Nevertheless, a possible beneficial role in therapeutic response of various solid tumors with different types of therapy have been shown, [27],[28],[29] as well as the potential of using quantitative parameters for FLT uptake such as SUV. [19]

This is the first report of 18 F-FLT-PET to assess the effect of the MEK inhibitor Selumetinib. In this limited study, FLT-PET-CT as an early predictor of response on Selumetinib is interesting. Further investigation of FLT-PET as a biomarker of early treatment response is needed.

 
   References Top

1.Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351 Pt 2:289-305.  Back to cited text no. 1
    
2.Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1 / 2 inhibitor AZD6244 (ARRY-142886): A phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010;16:1613-23.  Back to cited text no. 2
    
3.Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1 / 2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 2011;29:1021-8.  Back to cited text no. 3
    
4.Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, et al. Phase II, open-label, randomized trial of the MEK1 / 2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-67.  Back to cited text no. 4
    
5.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.  Back to cited text no. 5
    
6.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.  Back to cited text no. 6
    
7.Capirci C, Rampin L, Erba PA, Galeotti F, Crepaldi G, Banti E, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 2007;34:1583-93.  Back to cited text no. 7
    
8.De Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, et al. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007;48:1592-8.  Back to cited text no. 8
    
9.De Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008;19:348-52.  Back to cited text no. 9
    
10.Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004;45:17-21.  Back to cited text no. 10
    
11.Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007;298:2289-95.  Back to cited text no. 11
    
12.Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.  Back to cited text no. 12
    
13.Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, et al. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'- 3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 2006;12:4590-7.  Back to cited text no. 13
    
14.Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006;66:11055-61.  Back to cited text no. 14
    
15.Francis DL, Visvikis D, Costa DC, Arulampalam TH, Ownsend C, Luthra SK, et al. Potential impact of [18F]3'- deoxy-3'- fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-94.  Back to cited text no. 15
    
16.Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'- [(18)F]fluoro-3'- deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002;29:1174-81.  Back to cited text no. 16
    
17.Van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, et al. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 2005;46:400-4.  Back to cited text no. 17
    
18.Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, et al. In vivo validation of 3'deoxy-3'- [(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23.  Back to cited text no. 18
    
19.De Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, et al. Reproducibility of quantitative 18F-3'- deoxy-3'- fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009;36:389-95.  Back to cited text no. 19
    
20.Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-50S.  Back to cited text no. 20
    
21.Seaman ME, Contino G, Bardeesy N, Kelly KA. Molecular imaging agents: Impact on diagnosis and therapeutics in oncology. Expert Rev Mol Med 2010;12:e20.  Back to cited text no. 21
    
22.Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 2005;92:1599-610.  Back to cited text no. 22
    
23.McDonald DM, Choyke PL. Imaging of angiogenesis: From microscope to clinic. Nat Med 2003;9:713-25.  Back to cited text no. 23
    
24.Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 2003;21:3955-64.  Back to cited text no. 24
    
25.Bockisch A, Freudenberg LS, Schmidt D, Kuwert T. Hybrid imaging by SPECT/CT and PET/CT: Proven outcomes in cancer imaging. Semin Nucl Med 2009;39:276-89.  Back to cited text no. 25
    
26.Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, et al. Simultaneous PET-MRI: A new approach for functional and morphological imaging. Nat Med 2008;14:459-65.  Back to cited text no. 26
    
27.Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007;25:4714-21.  Back to cited text no. 27
    
28.Herrmann K, Wieder HA, Buck AK, Schöffel M, Krause BJ, Fend F, et al. Early response assessment using 3'- deoxy-3'- [18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007;13:3552-8.  Back to cited text no. 28
    
29.Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, et al. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-9.  Back to cited text no. 29
    


    Figures

  [Figure 1], [Figure 2]
 
 
    Tables

  [Table 1]


This article has been cited by
1 3'-Deoxy-3-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies
Jeong Eun Kim,Sun Young Chae,Jwa Hoon Kim,Hwa Jung Kim,Tae Won Kim,Kyu-pyo Kim,Sun Young Kim,Jae-Lyun Lee,Seung Jun Oh,Jae Seung Kim,Jin-Sook Ryu,Dae Hyuk Moon,Yong Sang Hong
European Journal of Nuclear Medicine and Molecular Imaging. 2019;
[Pubmed] | [DOI]
2 FLT-PET for early response evaluation of colorectal cancer patients with liver metastases: a prospective study
Marie Benzon Mogensen,Annika Loft,Marianne Aznar,Thomas Axelsen,Ben Vainer,Kell Osterlind,Andreas Kjaer
EJNMMI Research. 2017; 7(1)
[Pubmed] | [DOI]
3 MiR-92a mediates AZD6244 induced apoptosis and G1-phase arrest of lymphoma cells by targeting Bim
Xiao-Bin Lv,Xing Zhang,Lan Deng,Ling Jiang,Wei Meng,Zhigang Lu,Xiuju Wang
Cell Biology International. 2014; : n/a
[Pubmed] | [DOI]
4 Novel drug discovery opportunities for colorectal cancer
Joshua C Curtin
Expert Opinion on Drug Discovery. 2013; 8(9): 1153
[Pubmed] | [DOI]
5 The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice
Emma J. Haagensen,Huw D. Thomas,Ian Wilson,Suzannah J. Harnor,Sara L. Payne,Tommy Rennison,Kate M. Smith,Ross J. Maxwell,David R. Newell,Seema Singh
PLoS ONE. 2013; 8(12): e81763
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed2762    
    Printed164    
    Emailed0    
    PDF Downloaded338    
    Comments [Add]    
    Cited by others 5    

Recommend this journal